Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $540.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zevra Therapeutics Inc. (ZVRA) Competitors
The companies most similar to Zevra Therapeutics are Rezolute (RZLT), Theravance Biopharma (TBPH) and Avalo Therapeutics (AVTX). By market cap, Zevra Therapeutics ranks 7th of the 13 companies on this page; Pharming Group NV (PHAR) is the largest at $891.80M.
Peer Comparison
ZVRA's revenue growth of 44.9% is above the peer median of -10.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Zevra Therapeutics (ZVRA) | $540.30M | 11.6x | 3.7x | 52.8% | N/A | 44.9% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Peer median | $523.37M | 67.2x | 5.8x | 0.0% | -8.5% | -10.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Zevra Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
Frequently Asked Questions About ZVRA
Who are Zevra Therapeutics' main competitors?
The companies most similar to Zevra Therapeutics include Rezolute (RZLT), Theravance Biopharma (TBPH), Avalo Therapeutics (AVTX), Nuvectis Pharma (NVCT) and Tevogen Bio Holdings (TVGN), listed from the closest match.
Who is Zevra Therapeutics' biggest competitor?
Pharming Group NV (PHAR) is the largest of the similar companies at $891.80M; Rezolute (RZLT) is the closest match by business profile, size, sector and industry.
How does ZVRA stock compare with its competitors?
ZVRA's P/E is 11.6x against a peer median of 67.2x; its P/S is 3.7x against a peer median of 5.8x; its net margin is 52.8% against a peer median of 0.0%.
Which of Zevra Therapeutics' competitors pays a higher dividend?
Zevra Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Zevra Therapeutics bigger than its competitors?
No. Zevra Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Pharming Group NV (PHAR) at $891.80M.
ZVRA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors